HUMACYTE INC
HUMANASDAQTrading Snapshot
- Day Range
- $0.53 – $0.54
- 52-Week Range
- $0.53 – $2.93
- Volume
- $3.61B
- Avg Volume
- $2.89B
- Shares Outstanding
- 168.0M
- Next Earnings
- Oct 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $406,000
- P/E Ratio
- -1.1
- P/S Ratio
- 42.5x
- EPS (TTM)
- $-0.41
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +33.5%
Why Investors Own HUMA
- ✓High-growth profile — revenue up +50.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 48% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
HUMACYTE INC
HUMA
StockOtter · stockotter.spaceAbout HUMACYTE INC
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.56, representing a -2% change from its previous close.
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
Humacyte, Inc. (HUMA) reached $0.59 at the closing of the latest trading day, reflecting a +2.23% change compared to its last close.
Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today
Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months
– FDA authorizes extension of Symvess expiration dating from 18 months to 36 months – – Extended shelf life supported by additional stability data demonstrating Symvess continues to meet all established quality specifica